Answers are grounded in this paper and cite their sources.
Demonstrates increased protoporphyrin IX accumulation in cancer therapy with novel drug conjugates, suggesting enhanced treatment efficacy.
Background/Aim: Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is a widely accepted and minimally invasive treatment for various cancers. The Schiff base derivative N-3′,5′-dichloro-2′-hydroxybenzylidene-2-chloro-4-nitroaniline (TX-816) markedly enhances the efficacy of ALA-based PDT (ALA-PDT) by promoting intracellular accumulation of protoporphyrin IX (PpIX). However, TX-816 is unstable in aqueous solutions and rapidly hydrolyzes into the active agent 3, 5-dichlorosalicylaldehyde (DCSA) and 2-chloro-4-nitroaniline, thereby complicating its clinical application. Materials and Methods: We synthesized UTX-144 (a dasatinib derivative) and UTX-148 (a gefitinib derivative) by conjugating the tyrosine-kinase inhibitors dasatinib or gefitinib with DCSA via a Schiff base. These novel ALA-PDT sensitizers conjugate tyrosine kinase inhibitors (TKIs) that target ATP-binding cassette subfamily G member 2 (ABCG2), a PpIX efflux transporter, with DCSA via a Schiff base. Results: UTX-144 and UTX-148 showed strong ALA-PDT sensitization effects when used in combination with ALA, thereby increasing intracellular PpIX accumulation. Conclusion: This study successfully developed the novel ALA-PDT sensitizers UTX-144 and UTX-148.
No takes yet. Share an insight, caveat, or question.
Shinohara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: